Skip to main content
University of Wisconsin-Madison

Events

Events in October 2024

Sunday Monday Tuesday Wednesday Thursday Friday Saturday
September 29, 2024(1 event)


September 29, 2024

Join us for the White Coat Ceremony Honoring the Doctor of Pharmacy Class of 2028 as they advance into the profession of pharmacy.

Each student my invite up to 5 guests and is responsible for distributing tickets to their respective guests.  Additional details will be provided directly to students as they become available.  Please direct questions to WSPS Team Professionalism

1308 West Dayton Street
Madison, WI 53715
United States

September 30, 2024
October 1, 2024
October 2, 2024
October 3, 2024
October 4, 2024(1 event)


October 4, 2024

Pharmaceutical Sciences Seminar Series

 

(Drug DISCOVERY Specific Seminar)

  • Dan Flaherty, PhD
  • Purdue University

 

Hosted by Jennifer Golden

777 Highland Ave
Madison, WI 53705
United States

October 5, 2024
October 6, 2024
October 7, 2024
October 8, 2024
October 9, 2024(4 events)


October 9, 2024

Online


October 9, 2024

Online


October 9, 2024

Online

October 10, 2024
October 11, 2024(2 events)


October 11, 2024

Online

October 12, 2024
October 13, 2024
October 14, 2024
October 15, 2024(1 event)
October 16, 2024(1 event)
October 17, 2024(1 event)


October 17, 2024

See your Canvas Advising Hub for more information. Contact Chelsea Wimmer with questions. 

October 18, 2024
October 19, 2024
October 20, 2024
October 21, 2024
October 22, 2024
October 23, 2024
October 24, 2024(1 event)


October 24, 2024

Have questions or want to learn more about UW-Madison’s Pharmaceutical Sciences PhD Program?

A

Join Professor Lara Collier, Director of Graduate Studies, for a Virtual Drop-In Office Hour:

Thursday, Oct 24, 2024
6:30 – 7:30 PM CST

Register for this event

Virtual Event

October 25, 2024
October 26, 2024
October 27, 2024
October 28, 2024(1 event)


October 28, 2024

This event runs from 4:30 on 10/28/24 to 12 Noon on 10/29/24.

 

 

Online

October 29, 2024(3 events)


October 29, 2024

This event runs from 4:30 on 10/28/24 to 12 Noon on 10/29/24.

Online


October 29, 2024

 This event runs from 4:30 PM 10/29/24 to 12 Noon on 10/30/24. 

Online

October 30, 2024(2 events)


October 30, 2024

 This event runs from 4:30 PM 10/29/24 to 12 Noon on 10/30/24. 

Online


October 30, 2024

 This event runs from 4:30 PM 10/30/24 to 12 Noon on 10/31/24. 

Online

October 31, 2024(1 event)


October 31, 2024

 This event runs from 4:30 PM 10/30/24 to 12 Noon on 10/31/24. 

Online

November 1, 2024(2 events)

November 1, 2024

Block 4 runs from September 23 to November 1, 2024 .

Online


November 1, 2024

Pharmaceutical Sciences Seminar Series

 

(Drug DISCOVERY Specific Seminar)

  • Kathie Seley-Radtke, PhD
  • University of Maryland

Development of Pan-Viral Nucleoside Inhibitors

The severity and rapid spread of the coronavirus pandemic served to drive home that we were completely unprepared to fight such an outbreak. As a result, it became clear that there was a critical need for small molecule, orally bioavailable, broad-spectrum drugs that could be stockpiled and readily distributed when the next outbreak occurs. In that regard, for many years nucleos(t)ides have maintained a prominent role as one of the cornerstones of antiviral and anticancer therapeutics, and numerous scaffolds in nucleos(t)ide and nucleic acid drug design have been pursued. One such approach involves adding flexibility to the sugar moieties of nucleos(t)ides, for example, in the highly successful anti-HIV/HBV drug Tenofovir developed by Antonín Holý. In contrast, introduction of flexibility to the nucleobase scaffold has only more recently gained significance with the invention of our fleximers. This modification has led to a significant improvements in antiviral activity, and in some cases endowing the nucleoside with potent broad-spectrum activity across several viral families, when the parent rigid nucleoside was inactive. Another advantage observed is the ability to avoid resistance mechanisms related to point mutations by engaging secondary amino acid residues not previously involved in the mechanism of action. A second series of nucleosides being pursued in our group, involves insertion of a heterocyclic spacer ring in between the two moieties of the bicyclic purine ring system, forming an expanded tricyclic nucleoside with increased aromaticity. This modification has also led to potent antiviral activity, again targeting several different pathogens of pandemic concern. A brief history of their design, synthesis, and recent antiviral findings for these innovative nucleos(t)ide scaffolds will be discussed.

Hosted by Jennifer Golden

777 Highland Ave
Madison, WI 53705
United States

November 2, 2024